DexCom (NASDAQ:DXCM) Stock Acquired Sen. John Boozman

Senator John Boozman (R-Arkansas) recently bought shares of DexCom, Inc. (NASDAQ:DXCM). In a filing disclosed on February 15th, the Senator disclosed that they had bought between $1,001 and $15,000 in DexCom stock on January 26th.

Senator John Boozman also recently made the following trade(s):

• Sold $1,001 – $15,000 in shares of Omnicom Group (NYSE:OMC) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Eaton (NYSE:ETN) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of Caterpillar (NYSE:CAT) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of iShares S&P 500 Growth ETF (NYSEARCA:IVW) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Fiserv (NASDAQ:FISV) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Union Pacific (NYSE:UNP) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of CVS Health (NYSE:CVS) on 1/29/2026.
• Purchased $1,001 – $15,000 in shares of PayPal (NASDAQ:PYPL) on 1/29/2026.
• Sold $1,001 – $15,000 in shares of Micron Technology (NASDAQ:MU) on 1/26/2026.
• Sold $1,001 – $15,000 in shares of abrdn Physical Palladium Shares ETF (NYSEARCA:PALL) on 1/23/2026.

DexCom Trading Up 7.6%

Shares of DXCM stock opened at $70.02 on Monday. The company has a market cap of $26.95 billion, a PE ratio of 33.34, a price-to-earnings-growth ratio of 1.25 and a beta of 1.49. DexCom, Inc. has a 1 year low of $54.11 and a 1 year high of $93.25. The stock’s 50 day simple moving average is $69.03 and its two-hundred day simple moving average is $69.47. The company has a debt-to-equity ratio of 0.45, a current ratio of 1.88 and a quick ratio of 1.59.

DexCom (NASDAQ:DXCM) last released its quarterly earnings results on Thursday, February 12th. The medical device company reported $0.68 earnings per share for the quarter, beating the consensus estimate of $0.65 by $0.03. The company had revenue of $1.26 billion for the quarter, compared to analyst estimates of $1.25 billion. DexCom had a return on equity of 32.12% and a net margin of 17.94%.DexCom’s quarterly revenue was up 13.1% compared to the same quarter last year. During the same quarter in the prior year, the firm posted $0.45 EPS. Research analysts predict that DexCom, Inc. will post 2.03 earnings per share for the current year.

Wall Street Analysts Forecast Growth

Several equities analysts recently commented on the stock. Wall Street Zen downgraded shares of DexCom from a “strong-buy” rating to a “buy” rating in a report on Sunday, November 16th. UBS Group decreased their price target on DexCom from $106.00 to $95.00 and set a “buy” rating for the company in a research note on Monday, November 3rd. Canaccord Genuity Group set a $95.00 target price on DexCom and gave the stock a “buy” rating in a research note on Friday. Citigroup restated a “buy” rating and issued a $77.00 price target (up from $75.00) on shares of DexCom in a report on Thursday, December 11th. Finally, Morgan Stanley reiterated an “overweight” rating on shares of DexCom in a report on Monday, January 12th. Two equities research analysts have rated the stock with a Strong Buy rating, seventeen have given a Buy rating, five have given a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat.com, DexCom currently has an average rating of “Moderate Buy” and a consensus target price of $85.27.

Hedge Funds Weigh In On DexCom

Several institutional investors have recently bought and sold shares of the business. Andra AP fonden purchased a new position in shares of DexCom in the 2nd quarter valued at $26,000. Twin Peaks Wealth Advisors LLC purchased a new position in DexCom in the second quarter valued at about $26,000. SJS Investment Consulting Inc. lifted its position in shares of DexCom by 4,800.0% during the third quarter. SJS Investment Consulting Inc. now owns 392 shares of the medical device company’s stock valued at $26,000 after buying an additional 384 shares during the last quarter. Financial Consulate Inc. bought a new stake in shares of DexCom in the 3rd quarter valued at about $29,000. Finally, CVA Family Office LLC grew its position in shares of DexCom by 48.5% in the 4th quarter. CVA Family Office LLC now owns 450 shares of the medical device company’s stock worth $30,000 after buying an additional 147 shares during the last quarter. 97.75% of the stock is owned by hedge funds and other institutional investors.

More DexCom News

Here are the key news stories impacting DexCom this week:

• Positive Sentiment: Q4 results beat expectations: DexCom reported $0.68 EPS vs. $0.65 consensus and $1.26B in revenue (≈13% YoY); management reiterated 2026 guidance, supporting near-term outlook. Dexcom beats quarterly estimates
• Positive Sentiment: G7 15‑day sensor rollout and margin gains cited as growth drivers — management pointed to product adoption and improving margins as catalysts for revenue and profitability expansion. G7 rollout drives growth
• Positive Sentiment: Mizuho raised its price target to $90 (outperform), signaling confidence in longer‑term upside and helping buy‑side sentiment. Mizuho price target raise
• Positive Sentiment: BTIG reaffirmed a Buy rating with an $85 target, adding to analyst support that underpins the rally. BTIG reaffirmation
• Positive Sentiment: Product/AI initiative — the Stelo AI upgrade aims to deepen consumer metabolic-health engagement, which could expand recurring usage and ARPU over time. Stelo AI upgrade
• Neutral Sentiment: Analyst activity is mixed overall: several firms maintained or raised targets while at least one adjusted its price target (see below). This creates both support and some variability in near-term expectations. Wall Street analyst targets
• Neutral Sentiment: Trading indicators: intraday volume is notably above the stock’s average, which amplifies price moves but can increase short-term volatility. (Background market data)
• Neutral Sentiment: Short‑interest notices in the data feed show anomalous zero/NaN values and a 0.0 days‑to‑cover figure — the data appears unreliable and should be treated cautiously by traders monitoring short activity.
• Negative Sentiment: Wells Fargo trimmed its price target from $93 to $85 despite keeping an Overweight rating, a modest negative signal that reduces the high‑end analyst consensus. Wells Fargo target cut

About Senator Boozman

John Boozman (Republican Party) is a member of the U.S. Senate from Arkansas. He assumed office on January 3, 2011. His current term ends on January 3, 2029. Boozman (Republican Party) ran for re-election to the U.S. Senate to represent Arkansas. He won in the general election on November 8, 2022. Boozman won re-election in 2016. He faced Democrat Conner Eldridge, Libertarian Frank Gilbert, and write-in candidate Jason Tate in the general election. Arkansas’ U.S. Senate race was rated as safely Republican in 2016. Boozman began his political career in the U.S. House. He won a special election in 2001 and served in that position until his election to the Senate in 2010. Prior to his political career, Boozman worked as an optometrist. As of a 2014 analysis of multiple outside rankings, Boozman is an average Republican member of Congress, meaning he will vote with the Republican Party on the majority of bills. Below is an abbreviated outline of Boozman’s academic, professional, and political career: 2011-Present: U.S. Senator from Arkansas 2001-2011: U.S. Representative from Arkansas 1977: Graduated from Southern College of Optometry

DexCom Company Profile

DexCom, Inc is a medical device company that develops, manufactures and distributes continuous glucose monitoring (CGM) systems for people with diabetes. Its products are designed to provide near real-time glucose readings, trend information and alerts to help patients and clinicians manage insulin dosing and reduce hypoglycemia and hyperglycemia. The company’s offerings combine wearable glucose sensors, wireless transmitters and software applications that deliver data to smartphones, dedicated receivers and cloud-based platforms for remote monitoring.

Founded in 1999 and headquartered in San Diego, California, DexCom has focused its business on advancing CGM technology and expanding clinical use beyond traditional insulin-dependent populations.